Study
| Phase I/II, first-in-human trial |
| Relapsed/refractory multiple myeloma |
| Livoseltamab 50mg (n=104) vs 200mg (n=117) |
Efficacy
| ORR: 71% (200mg) vs 48% (50mg) |
| mDOR: 29.4 mos (95% CI, 19.2 to not evaluable) (200mg) |
| mOS: 31.4 mos (95% CI, 21.6 to not evaluable) (200mg) |
| Probability of being progression-free at 12 mos: 70% (200mg) |
Safety
| Grade >=3 AE: neutropenia (18.8% vs 26.9%), anemia (30.8% vs 37.5%) |
| Discontinuation due to TEAEs: 18.8% (200mg) including 7.7% related to linvoseltamab |
| Grade 3-4 infections: 33.3% vs 28.8% |
| Treatment-related deaths: 5.1% (200mg) |
J Clin Oncol 2024;42:2702-2712
Bumma N,Richter J,Jagannath S Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
http://doi.org/10.1200/JCO.24.01008
Reviewed by Elvin Chalabiyev, MD on Sep 3, 2025
